{
    "organizations": [],
    "uuid": "aa63b33608196b2e4967cf49f5e65beb242c2bef",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biohaven-pharma-says-safety-profil/brief-biohaven-pharma-says-safety-profile-thus-far-favours-rimegepant-in-comparison-with-allergans-ubrogepant-idUSFWN1R80OV",
    "ord_in_thread": 0,
    "title": "BRIEF-Biohaven Pharma Says Safety Profile Thus Far Favours Rimegepant, In Comparison With Allergan's Ubrogepant",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 26 (Reuters) - Allergan Plc:\n* BIOHAVEN PHARMACEUTICAL SAYS IN TERMS OF COMPARISON OF RIMEGEPANT WITH ALLERGAN’S UBROGEPANT, THE SAFETY PROFILE THUS FAR FAVOURS RIMEGEPANT - CONF CALL\n* BIOHAVEN PHARMACEUTICAL SAYS “WE’RE GONNA HAVE A LOT OF OPTIONALITY WITH REGARD TO HOW WE COMMERCIALIZE” RIMEGEPANT - CONF CALL Further company coverage:\n ",
    "published": "2018-03-26T21:36:00.000+03:00",
    "crawled": "2018-03-27T11:40:42.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "allergan",
        "plc",
        "biohaven",
        "pharmaceutical",
        "say",
        "term",
        "comparison",
        "rimegepant",
        "allergan",
        "ubrogepant",
        "safety",
        "profile",
        "thus",
        "far",
        "favour",
        "rimegepant",
        "conf",
        "call",
        "biohaven",
        "pharmaceutical",
        "say",
        "gon",
        "na",
        "lot",
        "optionality",
        "regard",
        "commercialize",
        "rimegepant",
        "conf",
        "call",
        "company",
        "coverage"
    ]
}